MX2011012595A - Composicion farmaceutica que comprende el uso de derivados de prostaglandina para modular las funciones mediadas por claudina y el tratamiento de trastornos dermatologicos. - Google Patents

Composicion farmaceutica que comprende el uso de derivados de prostaglandina para modular las funciones mediadas por claudina y el tratamiento de trastornos dermatologicos.

Info

Publication number
MX2011012595A
MX2011012595A MX2011012595A MX2011012595A MX2011012595A MX 2011012595 A MX2011012595 A MX 2011012595A MX 2011012595 A MX2011012595 A MX 2011012595A MX 2011012595 A MX2011012595 A MX 2011012595A MX 2011012595 A MX2011012595 A MX 2011012595A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
treatment
modulating
dermatological disorders
prostaglandin derivatives
Prior art date
Application number
MX2011012595A
Other languages
English (en)
Inventor
Ryuji Ueno
Sachiko Tsukita
Original Assignee
Univ Osaka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Osaka filed Critical Univ Osaka
Publication of MX2011012595A publication Critical patent/MX2011012595A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe una composición farmacéutica para la modulación de una función mediada por claudina en un sujeto mamífero, que comprende administrar a un sujeto en necesidad del mismo de una cantidad efectiva de un derivado de ácido graso específico; la solicitud también describe un método para el tratamiento de una enfermedad dermatológica y un método para modular una expresión de una claudina en un sujeto mamífero que utiliza el mismo derivado de ácido graso como en lo anterior.
MX2011012595A 2009-05-27 2010-05-26 Composicion farmaceutica que comprende el uso de derivados de prostaglandina para modular las funciones mediadas por claudina y el tratamiento de trastornos dermatologicos. MX2011012595A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18146309P 2009-05-27 2009-05-27
PCT/JP2010/059300 WO2010137731A1 (en) 2009-05-27 2010-05-26 Pharmaceutical composition comprising prostaglandin derivatives for use in modulating claudin mediated functions and in the treatment of dermatological disorders

Publications (1)

Publication Number Publication Date
MX2011012595A true MX2011012595A (es) 2011-12-16

Family

ID=42352317

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012595A MX2011012595A (es) 2009-05-27 2010-05-26 Composicion farmaceutica que comprende el uso de derivados de prostaglandina para modular las funciones mediadas por claudina y el tratamiento de trastornos dermatologicos.

Country Status (16)

Country Link
US (1) US20100305203A1 (es)
EP (1) EP2435049A1 (es)
JP (1) JP2012528077A (es)
KR (1) KR20120031954A (es)
CN (1) CN102448463A (es)
AR (1) AR076929A1 (es)
AU (1) AU2010253720A1 (es)
BR (1) BRPI1011658A2 (es)
CA (1) CA2761250A1 (es)
IL (1) IL216218A0 (es)
MX (1) MX2011012595A (es)
NZ (1) NZ596555A (es)
RU (1) RU2011153196A (es)
TW (1) TW201102070A (es)
WO (1) WO2010137731A1 (es)
ZA (1) ZA201109532B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
WO2023102209A1 (en) * 2021-12-03 2023-06-08 The University Of Chicago Claudin inhibitors and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
JPH01265021A (ja) * 1987-10-29 1989-10-23 Hercon Lab Corp 薬理学的活性物質を含有する組成物を動物組織に制御放出および供給するための物品
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
JPH04300833A (ja) * 1991-03-29 1992-10-23 Green Cross Corp:The プロスタグランジンｅ１　含有脂肪乳剤充填噴霧剤
JP2802912B2 (ja) * 1995-08-16 1998-09-24 小野薬品工業株式会社 プロスタグランジンｅ１エステル、それらを含有するリポソーム製剤、およびそれらを含有する医薬
TW367324B (en) * 1995-08-16 1999-08-21 Ono Pharmaceutical Co Prostaglandin derivatives
KR100227541B1 (ko) * 1995-08-25 1999-11-01 우에노 도시오 프로스타글란딘 유도체
JPH09124593A (ja) * 1995-08-25 1997-05-13 Ono Pharmaceut Co Ltd プロスタグランジンｅ１エステル、それらを含有するリポソーム製剤、およびそれらを含有する医薬
AU2003228819A1 (en) * 2002-05-03 2003-11-17 Combinatorx, Incorporated Combinations for the treatment of inflammatory skin disorders
JP2005139194A (ja) * 2002-08-09 2005-06-02 Taisho Pharmaceut Co Ltd 止痒剤
US7737182B2 (en) * 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
HUE029417T2 (en) * 2002-10-10 2017-02-28 Ono Pharmaceutical Co Microspheres containing ONO-1301
TWI432201B (zh) * 2005-03-04 2014-04-01 Sucampo Ag 11-去氧基-前列腺素化合物用於治療週邊血管疾病之用途
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
CN101180096B (zh) * 2005-03-21 2015-04-22 苏坎波公司 用于治疗粘膜疾病的方法和组合物
US8871752B2 (en) * 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
CN101318948B (zh) * 2008-04-01 2011-04-27 上海天伟生物制药有限公司 鲁比前列酮晶体、其制备方法及用途

Also Published As

Publication number Publication date
TW201102070A (en) 2011-01-16
RU2011153196A (ru) 2013-07-10
CA2761250A1 (en) 2010-12-02
JP2012528077A (ja) 2012-11-12
IL216218A0 (en) 2012-01-31
AU2010253720A1 (en) 2011-12-08
CN102448463A (zh) 2012-05-09
US20100305203A1 (en) 2010-12-02
AR076929A1 (es) 2011-07-20
EP2435049A1 (en) 2012-04-04
KR20120031954A (ko) 2012-04-04
NZ596555A (en) 2014-01-31
WO2010137731A1 (en) 2010-12-02
BRPI1011658A2 (pt) 2018-03-06
ZA201109532B (en) 2012-09-26

Similar Documents

Publication Publication Date Title
SG10201400685SA (en) Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
NZ720946A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX2011010347A (es) Derivados sustituidos de azoantraceno, composiciones farmaceuticas y metodos de uso de los mismos.
BRPI0916456B8 (pt) compostos lipídicos, composições de suplemento alimentar, farmacêuticas e lipídicas, método para produção de compostos lipídicos e uso de compostos lipídicos
MX336452B (es) Complejo aclarador de la piel, uso del complejo, composicion cosmetica o farmaceutica que comprende el complejo y metodo para su aplicacion.
MX2009004980A (es) Composiciones topicas que comprenden polihidroxi acidos y/o lactonas para efectos cutaneos mejorados de farmacos terapeuticos oxidantes.
MY161607A (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions
WO2013116753A8 (en) Fatty acids as anti-inflammatory agents
WO2007098142A3 (en) Oxazole ketones as modulators of fatty acid amide hydrolase
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
MX2016008496A (es) Composiciones de acido graso de liberacion controlada para usarse en recontruccion corporal y formacion del cuerpo.
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
WO2010107251A2 (ko) 파카스트리사민을 유효성분으로 함유하는 과증식성 피부질환과 악성흑생종의 예방 또는 치료용 약학적 조성물
MX2010008433A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares.
BR112013026644A2 (pt) método para a modulação da atividade de citocina
WO2009111688A3 (en) All-trans retinoid esters as active pharmaceutical ingredients, oral and topical dosage form compositions thereof, and methods of treating skin conditions thereof
MX2011012595A (es) Composicion farmaceutica que comprende el uso de derivados de prostaglandina para modular las funciones mediadas por claudina y el tratamiento de trastornos dermatologicos.
MX2009012713A (es) Nuevos derivados de acido 3-fenil acrilico de receptores de tipo ppar, su metodo de preparacion y su uso en composiciones cosmeticas o farmaceuticas.
UA112418C2 (uk) Терапевтичний болезаспокійливий засіб
WO2012075093A3 (en) Topical formulations for administration of omega-3 fatty acids
MX2012000768A (es) Derivados de tazaroteno.
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA108233C2 (uk) Модулятори активності гідролази амідів жирних кислот

Legal Events

Date Code Title Description
FA Abandonment or withdrawal